RA Capital Management’s iTeos Therapeutics ITOS Stock Holding History

RA Capital Management’s Portfolio ITOS Stock Details ITOS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-3,649,057	Closed	-$21.8M	–	77
2025 Q1	$21.8M	Buy	3,649,057 +1,556,798	+74%	+$11.4M	0.36%	40
2024 Q4	$16.1M	Sell	2,092,259 -1,092,452	-34%	-$9.39M	0.21%	65
2024 Q3	$32.5M	Sell	3,184,711 -332,548	-9%	-$5.07M	0.37%	47
2024 Q2	$52.2M	Sell	3,517,259 -900,000	-20%	-$12.9M	0.69%	35
2024 Q1	$60.3M	Hold	4,417,259	–	–	0.77%	37
2023 Q4	$48.4M	Hold	4,417,259	–	–	0.76%	33
2023 Q3	$48.4M	Hold	4,417,259	–	–	0.95%	30
2023 Q2	$58.5M	Hold	4,417,259	–	–	1.1%	28
2023 Q1	$60.1M	Hold	4,417,259	–	–	1.36%	26
2022 Q4	$86.3M	Hold	4,417,259	–	–	1.75%	21
2022 Q3	$84.1M	Hold	4,417,259	–	–	1.8%	17
2022 Q2	$91M	Hold	4,417,259	–	–	2.43%	12
2022 Q1	$142M	Hold	4,417,259	–	–	3.1%	5
2021 Q4	$206M	Hold	4,417,259	–	–	3.63%	3
2021 Q3	$119M	Hold	4,417,259	–	–	1.65%	20
2021 Q2	$113M	Buy	4,417,259 +1	+0%	+$24	1.82%	13
2021 Q1	$151M	Hold	4,417,258	–	–	2.28%	10
2020 Q4	$149M	Hold	4,417,258	–	–	2.09%	9
2020 Q3	$109M	Buy	+4,417,258	New	+$119M	1.99%	15

Other funds holding ITOS

EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

BCM

Boxer Capital Management San Diego, California $1.33B AUM 864.5% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

RA Capital Management's ITOS Position: Q2 2025 in Review

RA Capital Management sold out of iTeos Therapeutics (ITOS) in Q2 2025, closing a stake of 3,649,057 shares — an estimated $21.8M sold.

RA Capital Management first reported a position in ITOS in Q3 2020 and held it in 19 quarters. The position peaked at $206M in Q4 2021. 137 funds tracked by Wall St. Rank hold ITOS as of Q2 2025.

RA Capital Management reported no remaining iTeos Therapeutics position as of Q2 2025 after selling out during the quarter.
RA Capital Management sold 3,649,057 iTeos Therapeutics shares in Q2 2025, an estimated $21.8M.
RA Capital Management first reported a position in iTeos Therapeutics in Q3 2020 and held it in 19 quarters.
RA Capital Management's iTeos Therapeutics position peaked at $206M in Q4 2021.
137 funds tracked by Wall St. Rank held iTeos Therapeutics as of Q2 2025.

Based on RA Capital Management's 13F filing for Q2 2025, filed 14 Aug 2025.